| |MAY 20249ABBOTT LAUNCHES NEXT GENERATION XIENCE SIERRA STENT IN INDIACOCRYSTAL PHARMA CONCLUDES ENROLMENT IN PHASE 2A STUDY OF CC-42344Cocrystal Pharma, Inc. reports that the randomized, double-blind, placebo-controlled phase 2a human challenge clinical study assessing the safety, tolerability, antiviral, and clinical measurements of its novel, oral PB2 inhibitor CC-42344, which is intended to treat influenza A, has enrolled 78 subjects. Using the Company's patented structure-based drug discovery platform technology, CC-42344 is a novel class of antiviral therapy that is intended to efficiently block a crucial stage in the viral replication and transcription of pandemic and seasonal influenza A, as well as other viruses."There is an urgent need for new influenza antivirals targeting highly pathogenic avian pandemic and seasonal influenza strains. It's gratifying to report the timely completion of enrollment in this important study, keeping us on track to announce topline results later this year. This human challenge study was conducted in the United Kingdom and was designed to evaluate a favorable safety profile, virological effects, and an improvement in clinical symptom for CC-42344 as a potential oral treatment for avian pandemic and seasonal influenza A," said Sam Lee, Ph.D., Cocrystal's president and co-CEO. "We are pleased to advance our robust pipeline with achievement of this important clinical development milestone as we continue to build our leadership in influenza therapeutics."CC-42344 is a prospective oral treatment for pandemic and seasonal influenza A. Cocrystal announced in March 2024 that it had received positive Pre-Investigational New Drug (Pre-IND) feedback from the FDA. This feedback included guidance and clarification on critical steps, such as designing a proposed phase 2b study protocol.Cocrystal also intends to conduct a phase 1 research in Australia using an inhalation version of CC-42344 as a possible influenza A therapy and post-exposure prevention. Recent preclinical findings demonstrated that inhaled CC-42344 had a high rate of lung delivery, superior lung exposure, effectiveness in influenza-infected human lung epithelia, and an acceptable safety profile. POAbbott, the global healthcare company,announced the launch of XIENCE Sierra Everolimus (drug) Eluting Coronary Stent System in India. XIENCE Sierra is one of the latest generation stents in the XIENCE family, now available to people suffering from blocked coronary arteries. For interventional cardiologists, it brings unparalleled safety to the most complex cases. Abbott has developed several tools and devices that have improved the angioplasty procedure over the years. Percutaneous coronary intervention (PCI), also called coronary angioplasty, is a nonsurgical, minimally invasive procedure that improves blood flow to the heart. Physicians use PCI to open blood vessels to the heart that are narrowed or blocked by plaque . Often, a small mesh tube called a stent is placed to keep the artery open. XIENCE is one of the most-used drug-eluting stents in the world. XIENCE Sierra improves upon previous versions of XIENCE with an enhanced stent design, a new delivery system, and unique sizes to help doctors treat challenging cases. XIENCE Sierra has the same highly specialized coating that lowers the likelihood of the artery becoming re-blocked, found in other XIENCE stents. XIENCE stents collectively have an unparalleled safety record from more than 120+ clinical trials involving 120,000 patients. As per published data, the stent has proved efficacy in difficult to treat, narrowed lesions and patients with complex conditions."We've launched XIENCE Sierra in India so that physicians can smoothly deliver the stent even in challenging cases," said Tushar Sharma, General Manager for Abbott's vascular business in India & South Asia. "The innovative design and improved deliverability mean physicians can access and unblock difficult-to-treat lesions with more flexibility and precision.With the incidence of coronary artery disease on the rise in India, it's important for us to provide technologies that help doctors optimally implant stents,so patients have the best outcomes possible." PO
< Page 8 | Page 10 >